FLT3 V592I

CI-VAR-00004565Explore in graph →CIViC 5482

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Myeloid Leukemia2
FLT3 V592I	(oncogenic)	Oncogenic	C	Supports Oncogenicity	2	rejected	EID12964 Longitudinal study analyzing blood samples over time for CHIP. The V592I was found with a VAF 0.53% (below normal CHIP threshold) in a control individual who did not develop AML. PMID 31004019 · Young et al., 2019 · Open in CIViC	civic
FLT3 V592I	(oncogenic)	Oncogenic	C	Supports Oncogenicity	2	submitted	EID12965 Found in whole blood of patient (ID# 4973, appendix 2) with AML, mutational profile included FLT3 V592I VAF 55%; FLT3-ITD VAF 25%, NPM1 c.863_864insCCTG VAF 25%, DNMT3A p.Arg882His VAF 43% PMID 37586297 · Hogg et al., 2023 · Open in CIViC	civic
Myeloproliferative Neoplasm

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.